Invitation to comment on a genetically modified (GM) banana field trial

Overview

The Gene Technology Act 2000, enacted in 2000, establishes Australia's regulatory framework for the control and oversight of genetically modified organisms (GMOs). The Act was introduced to address the need for a robust system to manage the potential risks posed by GMOs to human health, safety, and the environment. The Act empowers the Gene Technology Regulator to assess applications for the release of GMOs, ensuring that any potential risks are identified and managed appropriately. In this instance, the Office of the Gene Technology Regulator (OGTR) is currently evaluating a licence application for a field trial of genetically modified bananas, aimed at assessing their disease resistance and agronomic performance under field conditions. The Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) concluding that the proposed release poses negligible risk, with draft licence conditions set to limit the scope and impact of the trial. The OGTR is inviting public submissions to inform the finalisation of the RARMP and the decision on whether to issue the licence, reflecting the policy objective of balancing innovation with stringent risk management.

Scope and Application

The Gene Technology Act 2000, as it applies to genetically modified organisms, governs the regulation and oversight of the field trial of genetically modified (GM) bananas proposed by the Queensland University of Technology. This legislation specifically targets the entities and individuals involved in the research and development of gene technology, ensuring that all proposed activities adhere to stringent health and environmental safety standards. The Act applies to the entities conducting the research, the Regulator responsible for assessing and approving the trial, and the public who may be affected by the trial. Geographically, the Act operates at a national level under the Commonwealth jurisdiction, but the field trial itself is geographically confined to Litchfield Municipality in the Northern Territory. The Act does not explicitly mention any exclusions or exemptions for this specific trial, but it generally allows for exceptions where negligible risk to health and the environment is determined. The Act also allows for the extension or restriction of its application through subordinate instruments, which would further define the specific conditions under which the trial may proceed. The Regulator is currently seeking public consultation to finalise the Risk Assessment and Risk Management Plan, which will include any necessary licence conditions to mitigate risks associated with the trial.

Key Provisions

The primary sections of the Gazette (C2016G01360) concern the assessment and regulation of a proposed genetically modified (GM) banana field trial (Section 1). Section 2 details the application for the trial, submitted by the Queensland University of Technology under licence application DIR 146. The trial, which is aimed at assessing disease resistance and agronomic performance, is proposed for a site in the Litchfield Municipality, Northern Territory, and is set to run from January 2017 to January 2022. Notably, the GM bananas will not be intended for human consumption or animal feed (Section 3). A Risk Assessment and Risk Management Plan (RARMP) has been prepared, indicating that the proposed release poses negligible risk to human health and the environment (Section 4). The draft licence conditions include restrictions on the release's size, location, and duration, as well as measures to limit the spread and persistence of the GMOs and introduced genetic material (Section 5). The obligations imposed by the Act on the parties involved primarily centre on compliance with the RARMP and the draft licence conditions (Section 6). The Queensland University of Technology must adhere to the proposed restrictions and measures to ensure the safe conduct of the field trial (Section 7). The Gene Technology Regulator is tasked with reviewing the application, assessing the RARMP, and deciding whether to issue the licence based on the findings (Section 8). The Regulator must also consider any written submissions received from the public during the consultation period (Section 9). Any breach of the provisions outlined in the Act may result in various consequences, including civil and criminal penalties (Section 10). Although specific penalties are not detailed in the Gazette, breaches of similar gene technology regulations can lead to substantial fines and, in severe cases, imprisonment (Section 11). The exact penalties would depend on the nature and severity of the breach, as outlined in the relevant sections of the Gene Technology Act 2000 (Section 12). The Regulator is empowered to enforce compliance and take appropriate action against any non-compliance (Section 13).